| Literature DB >> 32154234 |
Tomoshi Tsuchiya1,2, Ryoichiro Doi1, Tomohiro Obata1, Go Hatachi1, Takeshi Nagayasu1.
Abstract
Biomaterials have been used for a long time in the field of medicine. Since the success of "tissue engineering" pioneered by Langer and Vacanti in 1993, tissue engineering studies have advanced from simple tissue generation to whole organ generation with three-dimensional reconstruction. Decellularized scaffolds have been widely used in the field of reconstructive surgery because the tissues used to generate decellularized scaffolds can be easily harvested from animals or humans. When a patient's own cells can be seeded onto decellularized biomaterials, theoretically this will create immunocompatible organs generated from allo- or xeno-organs. The most important aspect of lung tissue engineering is that the delicate three-dimensional structure of the organ is maintained during the tissue engineering process. Therefore, organ decellularization has special advantages for lung tissue engineering where it is essential to maintain the extremely thin basement membrane in the alveoli. Since 2010, there have been many methodological developments in the decellularization and recellularization of lung scaffolds, which includes improvements in the decellularization protocols and the selection and preparation of seeding cells. However, early transplanted engineered lungs terminated in organ failure in a short period. Immature vasculature reconstruction is considered to be the main cause of engineered organ failure. Immature vasculature causes thrombus formation in the engineered lung. Successful reconstruction of a mature vasculature network would be a major breakthrough in achieving success in lung engineering. In order to regenerate the mature vasculature network, we need to remodel the vascular niche, especially the microvasculature, in the organ scaffold. This review highlights the reconstruction of the vascular niche in a decellularized lung scaffold. Because the vascular niche consists of endothelial cells (ECs), pericytes, extracellular matrix (ECM), and the epithelial-endothelial interface, all of which might affect the vascular tight junction (TJ), we discuss ECM composition and reconstruction, the contribution of ECs and perivascular cells, the air-blood barrier (ABB) function, and the effects of physiological factors during the lung microvasculature repair and engineering process. The goal of the present review is to confirm the possibility of success in lung microvascular engineering in whole organ engineering and explore the future direction of the current methodology.Entities:
Keywords: decellularization; lung microvascular niche; lung regeneration; recellularization; tissue engineering
Year: 2020 PMID: 32154234 PMCID: PMC7047880 DOI: 10.3389/fbioe.2020.00105
Source DB: PubMed Journal: Front Bioeng Biotechnol ISSN: 2296-4185
FIGURE 1Advancements in lung microvascular niche reconstruction. The lung microvascular niche has been studied in the pathologies of lung disease and animal experimental models. Lung capillary mimics including Transwell® and lung-on-a-chip have been developed by researchers for understanding and simulating the lung microvascular niche. The cell replacement technique for whole lung organ engineering consequently needs to establish a microvascular niche in the natural scaffold. Suitable combination and numbers of cells with ideal mechanical stress will be necessary for whole lung organ engineering, which will be evaluated by microvascular passage, microvascular leakage, and gas exchange ability. ARDS, acute respiratory distress syndrome; TEER, trans-epithelial electrical resistance.
Summary of organ engineering using decellularized lung scaffolds.
| Mouse | 8 mM CHAPS | Mouse fibroblast A9 cells | Direct seeding | 3500 cells/m2–1.0 × 106 | 1–14 days |
| 0.1% Triton X-100, 0.1% SDS | Mouse C10 epithelial cells | Airway (Trachea) | 1.0 × 106–8.0 × 106 | 1–28 days | |
| 0.1% Triton X-100, 2% SDC | Mouse fetal lung cells | ||||
| Mouse bone marrow-derived mesenchymal stem cells | |||||
| Mouse embryonic stem cells | |||||
| Rat | 0.1% SDS | A549 cells | Direct seeding | 2000 cells/m2–2.0 × 106 | 1–28 days |
| 1% SDS | Mouse alveolar type II cells | Airway | 0.6 × 106–1.5 × 108 | 3–21 days | |
| 8 mM CHAPS | Mouse embryonic stem cells | Vascular | |||
| 0.1% Triton X-100, 0.1% SDS | Rat primary pulmonary endothelial cells | ||||
| 0.1% Triton X-100, 0.01% SDS | Rat primary epithelial cells | ||||
| 0.5% Triton X-100 | Rat neonatal lung cells | ||||
| 0.5% Triton X-100, 0.01% SDC | Rat lung distal epithelial cells | ||||
| 0.5% Triton X-100, 0.05% SDC | Rat lung microvascular endothelial cells | ||||
| 0.5% Triton X-100, 0.1% SDC | Rat adipose tissue-derived stem/stromal cells | ||||
| 1% Triton X-100, 2% SDC | Human umbilical cord endothelial cells | ||||
| 0.15 M NaOH | Human iPSC-derived endothelial cells | ||||
| Potassium laurate | Human iPSC-derived epithelial progenitor cells | ||||
| Pig | 0.5% SDS | Pig lung distal epithelial cell | Airway | 0.5 × 106–1.0 × 109 | 3–28 days |
| 1% SDS | Pig bone marrow-derived mesenchymal stem cells | Vascular | |||
| 2% SDS | Human umbilical cord endothelial cells | ||||
| 8 mM CHAPS | Human small airway epihtelial cells | ||||
| 0.1% Triton X-100, 2% SDC | Human epithelial progenitor cells | ||||
| 0.5% Triton X-100, 0.01% SDC | |||||
| 0.5% Triton X-100, 0.05% SDC | |||||
| 0.5% Triton X-100, 0.1% SDC | |||||
| 1%Triton X-100, 0.1% SDS | |||||
| Human | 0.1%SDS | Rat alveolar type II cells | Direct seeding | 2.5 × 104–4.0 × 106 | 1–12 days |
| 0.5% SDS | Human primary alveolar type II cells | Airway | 1.0 × 106–5.0 × 107 | 1–30 days | |
| 1% SDS | Human primary pulmonary endothelial cells | Vascular | |||
| 1.8 mM SDS | Human primary pulmonary epithelial cells | ||||
| 8 mM CHAPS | Human fetal lung cells | ||||
| 3% Tween 20, 4% SDC | Human lung fibroblast | ||||
| 0.1% Triton X-100, 2% SDS | Human bronchial epithelial cells | ||||
| 0.1% Triton X-100, 2% SDC | Human small airway epithelial cells | ||||
| 1% Triton X-100 | Human vascular endothelial cells (CBF12 positive cells) | ||||
| 3% Triton X-100 | Human bone marrow-derived mesenchymal stromal cells | ||||
| Human adipose tissue-derived mesenchymal stromal cells | |||||
| Human iPSC-derived alveolar type II cells | |||||
| Human iPSC-derived endothelial cells | |||||
| Human iPSC-derived epithelial progenitor cells | |||||
| Rhesus monkey | 0.01% Triton X-100, 0.1% SDS | Rhesus bone marrow-derived mesenchymal stromal cells | Direct seeding | 1.0 × 105 | 8 days |
| Rhesus macaque | 0.1% Triton X-100, 2% SDC | Rhesus adipose tissue-derived mesenchymal stromal cells | Airway (Bronchioles) | 1.5 × 106 | 7 days |
| Human embryonic stem cells | |||||
FIGURE 2ECM decomposition and reconstruction after recellularization. Lung ECMs consist of collagens, elastin, fibronectin, laminin, proteoglycans, and other constitutive proteins. After lung decellularization, a certain level of ECM damage occurs during decellularization. However, after recellularization, seeded cells secrete own ECM proteins which will change the ECM composition and finally affect lung functions including microvasculature permeability. ECM, extracellular matrix.
FIGURE 3Engineering of lung microvascular niche in the decellularized scaffold. Current engineered microvascular niches consist of incomplete epithelialization and endothelialization which causes vascular leakage, edema, platelet aggregation, and coagulation. Future engineered microvascular niches will achieve a strong ABB without vascular leakage and passable capillaries without coagulation by administrating surfactant, biologically active molecules, mechanical stresses, and/or suitable coating. ECM, extracellular matrix; ABB, alveolar-blood barrier.